Axsome Therapeutics Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $171 million, a 63% increase year-over-year.

Product Revenue Breakdown:

AUVELITY: $136.1 million, up 69% year-over-year.

SUNOSI: $32.8 million, up 35% year-over-year.

SYMBRAVO: $2.1 million in its first full quarter.

Gross-to-Net Discounts: AUVELITY and SUNOSI in the high 40% range, expected to rise to low 50% in Q4; SYMBRAVO at mid-70%.

Net Loss: $47.2 million ($0.94 per share), improved from a net loss of $64.6 million ($1.34 per share) in Q3 2024.

Cash Position: $325.3 million, up from $315.4 million at the end of 2024.

2Strategic Updates and Business Highlights

AUVELITY: Gaining traction in major depressive disorder (MDD) with strong demand and increased prescriber engagement, particularly in primary care.

SUNOSI: Steady growth with a significant share of prescriptions coming from obstructive sleep apnea (OSA) patients.

SYMBRAVO: Established a foundation for growth with over 5,000 prescriptions written in its first full quarter.

Pipeline Advancements:

Submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation.

Targeting NDA submission for AXS-12 in narcolepsy by year-end.

Planning Phase III trials for ADHD and fibromyalgia.

3Forward Guidance and Outlook

Commercial Growth: Continued focus on expanding prescriber base and patient access, particularly in primary care for AUVELITY.

Pipeline Development: Anticipation of multiple registrational trials and NDA submissions in the coming months.

Cash Flow Positivity: Management believes current cash reserves are sufficient to reach cash flow positivity based on existing operational plans.

4Bad News, Challenges, or Points of Concern

Increasing Gross-to-Net Discounts: Expected rise in discounts for AUVELITY and SUNOSI may impact net revenue.

Sales Force Expansion: While current sales force is performing well, future expansions will be necessary to support new product launches, which could increase costs.

Market Access: Although coverage for AUVELITY has improved, challenges remain in achieving near 100% coverage.

5Notable Q&A Insights

SYMBRAVO Launch: Early positive feedback from healthcare providers (HCPs) and patients, but management is cautious about further investments until deeper insights are gained.

AUVELITY in Primary Care: Recognized as a key growth driver; sales force expansion and direct-to-consumer campaigns are expected to enhance growth in this segment.

Regulatory Strategy: Management is focused on a standard review for AXS-05 and does not anticipate significant changes due to external factors like the government shutdown.

Narcolepsy Market Dynamics: Increased awareness and evolving epidemiology may drive growth, with a focus on both NT1 and NT2 patients. Overall, Axsome Therapeutics reported a strong quarter with significant revenue growth and strategic advancements in its pipeline, while also acknowledging challenges related to market access and increasing discounts.